• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Intern Med . Short-term Neuropsychiatric Outcomes and Quality of Life in COVID-19 Survivors

tetano

Editor, Senior Moderator
J Intern Med


. 2021 Feb 3.
doi: 10.1111/joim.13262. Online ahead of print.
Short-term Neuropsychiatric Outcomes and Quality of Life in COVID-19 Survivors


Ra?l M?ndez[SUP] 1 2 3 [/SUP], Vicent Balanz?-Mart?nez[SUP] 4 [/SUP], Sussy C Luperdi[SUP] 5 6 [/SUP], Itziar Estrada[SUP] 6 [/SUP], Ana Latorre[SUP] 2 [/SUP], Paula Gonz?lez-Jim?nez[SUP] 1 2 [/SUP], Laura Feced[SUP] 1 2 [/SUP], Leyre Bouzas[SUP] 1 2 [/SUP], Katheryn Y?pez[SUP] 1 2 [/SUP], Ana Ferrando[SUP] 1 2 [/SUP], David Herv?s[SUP] 7 [/SUP], Enrique Zald?var[SUP] 1 2 [/SUP], Soledad Reyes[SUP] 1 2 [/SUP], Michael Berk[SUP] 8 9 [/SUP], Rosario Men?ndez[SUP] 1 2 6 10 [/SUP]



Affiliations

Abstract

Background: The general medical impacts of coronavirus (COVID-19) are increasingly appreciated. However, its impact on neurocognitive, psychiatric health and quality of life (QoL) in survivors after the acute phase is poorly understood. We aimed to evaluate neurocognitive function, psychiatric symptoms, and QoL in COVID-19 survivors shortly after hospital discharge.
Methods: This was a cross-sectional analysis of a prospective study of hospitalised COVID-19 survivors followed-up for 2 months after discharge. A battery of standardised instruments evaluating neurocognitive function, psychiatric morbidity, and QoL (mental and physical components) was administered by telephone.
Results: Of the 229 screened patients, 179 were included in the final analysis. Among survivors, the prevalence of moderately impaired immediate verbal memory and learning was 38%, delayed verbal memory (11.8%), verbal fluency (34.6%), and working memory (executive function) (6.1%), respectively. Moreover, 58.7% of patients had neurocognitive impairment in at least one function. Rates of positive screening for anxiety, depression, and post-traumatic stress disorder were 29.6%, 26.8%, and 25.1%, respectively. In addition, 39.1% of the patients had psychiatric morbidity. Low QoL for physical and mental components was detected in 44.1% and 39.1% of patients, respectively. Delirium and psychiatric morbidity were associated with neurocognitive impairment and female gender was related with psychiatric morbidity.
Conclusion: Hospitalised COVID-19 survivors showed a considerable prevalence of neurocognitive impairment, psychiatric morbidity, and poor QoL in the short-term. It is uncertain if these impacts persist over the long-term.

Keywords: COVID-19; neurocognitive; psychiatric morbidity; quality of life; sequelae.
 
Back
Top Bottom